SCHEMBL15079494

SCHEMBL15079494

Nc1ccc(-c2cn3c(n2)sc2nc(NCCN4CCOCC4)ccc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 0.64
TSHR P16473 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CD274 Q9NZQ7 1/20 0.42
KDR P35968 2/20 0.42
BMPR1B O00238 1/20 0.42
MUSK O15146 1/20 0.42
EPHB6 O15197 1/20 0.42
MAP3K7 O43318 1/20 0.42
RIPK2 O43353 1/20 0.42
PAK3 O75914 1/20 0.42
STK10 O94804 1/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15079510 0.87 FLT3 (0.62) FLT3TSHRALDH1A1CYP1A2CYP3A4
SCHEMBL15079653 0.81 FLT3 (0.57) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL15079466 0.79 FLT3 (1.00) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL15079492 0.79 FLT3 (0.49) FLT3TSHRALDH1A1CYP1A2CYP3A4
SCHEMBL73364 0.75 FLT3 (0.56) FLT3TSHRMAPTKDRBMPR1B
SCHEMBL15079506 0.75 FLT3 (0.42) FLT3TSHRCYP1A2MAPTNPC1
SCHEMBL73506 0.74 FLT3 (0.62) FLT3MAPTKDRBMPR1BMUSK
SCHEMBL3453683 0.73 FLT3 (0.50) FLT3TSHRALDH1A1CYP1A2CYP3A4
SCHEMBL74009 0.73 FLT3 (0.65) FLT3TSHRMAPTRAB9AKDR
SCHEMBL17706303 0.72 FLT3 (0.65) FLT3KDRBMPR1BMUSKEPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763998-B1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2016-04-27 EP disclosed
US-9216997-B2 Tri-heterocyclic derivatives, preparation process and uses thereof SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2015-12-22 US disclosed
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2014-11-06 US disclosed
WO-2013091502-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF MAP3K15, MAP3K1, MAP3K5 FLT3 123/4885TSHR 1909/4885ALDH1A1 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.